Application of common bean (Phaseolus vulgaris L.) her b extract as a c omponent of complex therapy for diabetes mellitus

Abstract

A large number of plants are a rich source of biologically active compounds with specific pharmacological properties, and they do not cause unwanted side effects. The literature presents many medicinal plants with antidiabetic or hypoglycemic effects. So, for example, common bean (Phaseolus vulgaris L.) contains a large number of compounds with hypoglycemic, antioxidant and hypolipidemic effects and is used to treat diabetes, metabolic syndrome, hypertension, obesity, etc. Phaseolus vulgaris L. also reduces insulin resistance, inhibits α-amylase and the activity of dipeptidyl peptidase-4 enzyme. The new, improved technology of obtaining an enteric-dissolving encapsulated form of dry extract of the Phaseolus vulgaris L. herb allows to achieve a more complete
extraction of biologically active components. The aim of the work is clinical approval of a dry standardized extract of common bean herb (dietary supplement «Omnidia») to optimize and expand the possibilities of treatment of patients with diabetes. Material and methods. 16 patients with type 2 diabetes mellitus who were on various regimens of hypoglycemic therapy were involved in the study. In addition to standard therapy, they were prescribed 500 mg of the dietary supplement «Omnidia», in a dose of 3 capsules 3 times a day. Results. The clinical trial of a dry standardized extract of the Phaseolus vulgaris L. herb (dietary supplement «Omnidia») showed that the inclusion of this supplement in the complex therapy of patients with diabetes mellitus made it possible not to increase the insulin dose and/or not to intensify the hypoglycemic treatment in patients who were on a double tablet or injection therapy. 3 months after the standard treatment of diabetes mellitus with the addition of the dietary supplement «Omnidia» a decrease in the level of glycated hemoglobin and a significant increase in the rate of glomerular filtration were noted in patients. Also, good tolerability of the supplementation was recorded, which was reflected in a certain improvement of metabolic parameters. No side effects were observed while taking the dietary supplement «Omnidia». Conclusions. Taking into account the positive dynamics of glycated hemoglobin reduction in patients, we believe that the dietary supplement «Omnidia» can be included in the complex
therapy of patients with diabetes mellitus with concomitant obesity, dyslipidemia, and chronic kidney disease. We consider it expedient to recommend the long-term administration of the extract from Phaseolus vulgaris L. to the above-mentioned patients. The use of kidney bean for the treatment and prevention of diabetes mellitus and its complications is a promising strategy in medical practice.